Driven Brands Class Action Lawsuit (DRVN)

DRIVEN BRANDS (NASDAQ: DRVN)  Terwilliger v. Fitzpatrick, et al., No. 3:25-vs-00019 (Jan. 10, 2024, W.D.N.C.) – Verified shareholder derivative complaint filed against certain officers and directors of Driven Brands Holdings Inc. alleging breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets. Learn more about this case by clicking Driven Brands complaint.

If you own DRVN stock and have questions about potential legal claims, please email us at [email protected] or complete our Securities Class Action Questionnaire.

All submissions are confidential, evaluations of potential legal claims are free, and there is no obligation to take further action.

SEND US A MESSAGE

Contact Us

ADDRESS

Kehoe Law Firm, P.C.
2001 Market Street
Suite 2500
Philadelphia, PA 19103

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

TransMedics Group Securities Investigation (TMDX)

Kehoe Law Firm, P.C. is investigating potential securities class action claims on behalf of investors of TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQ: TMDX) stock after the Company’s stock price dropped significantly during intraday trading today.

INVESTORS OF TRANSMEDICS STOCK WITH FINANCIAL LOSSES MAY HAVE LEGAL OPTIONS AND ARE ENCOURAGED TO CONTACT KEHOE LAW FIRM, P.C. FOR A FREE EVALUATION OF POTENTIAL SECURITIES CLAIMS RELATED TO TMDX’S STOCK DROP.

The Company’s stock decline follows the release of a critical report by Scorpion Capital, accusing TransMedics of unethical business practices, including extortion, racketeering, and organ trafficking under the guise of a medical device company.

Key Allegations in the Scorpion Capital Report:

  • “Mafia-style” extortion, racketeering, and organ trafficking schemes
  • Kickbacks and billing fraud
  • Unreported device failures and off-label misuse of the Organ Care System

INVESTORS OF TRANSMEDICS STOCK WITH FINANCIAL LOSSES INTERESTED IN LEARNING MORE ABOUT THE CLASS ACTION INVESTIGATION ALSO CAN CLICK HERE, EMAIL [email protected], OR CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected].

Experian Faces Allegations of Mishandling Consumer Disputes

The Consumer Financial Protection Bureau (CFPB) has filed a lawsuit against Experian, one of the largest nationwide consumer reporting agencies, for failing to adequately investigate consumer disputes. According to the CFPB, Experian’s practices result in the inclusion of incorrect information on consumer credit reports, posing risks to consumers’ access to credit, employment, and housing.

“When consumers disputed errors on their credit reports, Experian conducted sham investigations rather than properly reviewing the disputes as required by federal law,” said CFPB Director Rohit Chopra. “Credit reporting errors can have serious consequences for a family’s finances, and it is critical that credit reporting giants follow the law.”

About Experian

Based in Costa Mesa, California, Experian is a subsidiary of Experian plc, a global data broker and analytics company headquartered in Ireland. As one of the nation’s three largest credit reporting conglomerates, Experian maintains data on most families in the United States. The company provides credit scores, credit reports, credit monitoring, and other related products to consumers and businesses. Experian collects information from data furnishers, such as banks, credit card companies, and debt collectors, and sells consumer reports to creditors and businesses to evaluate credit, employment, and housing opportunities.

Allegations Against Experian

The CFPB alleges that Experian has violated the Fair Credit Reporting Act (FCRA) by:

  1. Conducting Sham Investigations: Experian uses flawed intake procedures that fail to convey all relevant information about consumer disputes to original furnishers. The agency allegedly accepts furnishers’ responses uncritically, even when they are illogical or unsupported. Consumers receive notices with investigation results that are often confusing, incorrect, or inconsistent.
  2. Improperly Reinserting Inaccurate Information: Experian reportedly fails to implement tools to prevent the reinsertion of inaccurate information into consumer reports. This leads to consumers seeing previously disputed and corrected information reappear on their credit reports under the name of a new furnisher.
  3. Violating Consumer Protection Laws: Beyond FCRA violations, the CFPB claims Experian’s faulty dispute procedures and uncritical deference to furnishers’ responses constitute unfair practices under the Consumer Financial Protection Act. 

The Importance of the FCRA

The FCRA mandates that consumer reporting agencies ensure the accuracy of consumer reports and conduct thorough investigations into disputed information. It also requires agencies to follow specific procedures before reinserting information previously removed due to disputes.

Impact on Consumers

Inaccurate credit reporting can significantly harm consumers by:

  • Limiting access to loans, credit cards, and mortgages.
  • Affecting employment opportunities where credit checks are required.
  • Threatening access to rental housing or other critical services.

If you have experienced issues with credit reporting, it’s essential to know your rights and take proactive steps to dispute errors. Learn how to dispute inaccurate credit information.

Enforcement Action

Under the Consumer Financial Protection Act, the CFPB has the authority to take legal action against institutions that violate consumer financial protection laws. The CFPB’s lawsuit against Experian seeks to:

  • Halt the company’s unlawful practices.
  • Provide redress for harmed consumers.
  • Impose civil monetary penalties, with funds directed to the CFPB’s victims relief fund.

FAQ

What are my rights under the FCRA? You have the right to dispute inaccurate information on your credit report and expect a proper investigation by the reporting agency.

How can I dispute errors on my credit report? You can file a dispute directly with the credit reporting agency. Learn more about the process here.

Source: Consumerfinance.gov

Medical Debt Relief: CFPB Finalizes Landmark Credit Reporting Rule

CFPB Finalizes Rule to Remove Medical Bills from Credit Reports

The Consumer Financial Protection Bureau (CFPB) has taken a monumental step by finalizing a rule to eliminate medical bills from credit reports. This action is expected to transform the financial landscape for millions of Americans by removing unfair barriers to credit access caused by medical debt.

What the Rule Does:

  1. Removes Medical Debt from Credit Reports:
    • Medical bills will no longer appear on consumer credit reports, ensuring that past-due medical expenses do not impact credit scores.
    • This change will empower consumers to qualify for financial products like mortgages, car loans, and credit cards without the shadow of medical debt.
  2. Ensures Fair Lending Practices:
    • Lenders can no longer use medical debt as a factor in determining creditworthiness.
    • The CFPB emphasizes that medical debt is often an unreliable indicator of financial responsibility, as it frequently arises from emergencies or billing errors.
  3. Aligns with Consumer Protections:
    • This rule builds on previous actions by the CFPB, including efforts to address inaccuracies in credit reporting and ensure fair treatment of consumers.
    • Medical debt collections often stem from disputes over insurance coverage or billing errors, making their inclusion on credit reports particularly problematic.

Why This Matters:

Medical debt has been a significant hurdle for millions, disproportionately affecting those facing unexpected health crises or billing inaccuracies. The CFPB’s research has shown that the presence of medical debt on credit reports can unfairly penalize consumers, even when the debt is small or being disputed. By eliminating medical bills from credit reports, the CFPB aims to provide relief to consumers and promote fairer credit evaluations.

Implementation Details:

The rule, which amends Regulation V under the Fair Credit Reporting Act (FCRA), will take effect starting March 17, 2025. This timeline allows for a smooth transition while ensuring compliance across financial institutions. It also aligns with broader federal efforts to alleviate the burden of medical debt on American households.

A Broader Perspective:

This initiative is part of the CFPB’s ongoing commitment to protect consumers from financial harm and ensure equitable access to credit. By addressing the systemic issues associated with medical debt, the agency is helping millions of Americans achieve financial stability. Additionally, the CFPB’s efforts highlight the need for transparency and accuracy in credit reporting practices.

For more details, read the official CFPB announcement here.

NeueHealth Merger Investigation (NEUE)

NeueHealth Stock – Is the Proposed Acquisition of NeueHealth By An Affiliate of Its Controlling Shareholder Fair to NEUE Shareholders? –  

Kehoe Law Firm, P.C. is investigating potential claims on behalf of investors of NeueHealth, Inc. (“NeueHealth”) (NYSE: NEUE) regarding the adequacy and fairness of the proposed acquisition by NeueHealth’s controlling shareholder, New Enterprise Associates (“NEA”).

Under the terms of the proposed all-cash transaction, NEA’s affiliate would acquire NeueHealth for $7.33 per share. NEA already owns 53.8% of NeueHealth, raising significant concerns about the fairness and independence of the process undertaken by NeueHealth’s Board of Directors.

INVESTORS OF NEUEHEALTH STOCK CAN CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C. TO DISCUSS THE INVESTIGATION AND POTENTIAL LEGAL CLAIMS.

KEY INVESTIGATIVE CONCERNS:

Inadequate Deal Protections:  Although NeueHealth’s Board formed a special committee, it does not appear to have implemented customary safeguards, such as requiring a majority of the minority vote to approve the transaction.

Below-Market Valuation: The offer price of $7.33 per share is substantially below NeueHealth’s 52-week average price of $16.59 and its 52-week high of $31.00, suggesting an undervaluation that does not reflect NeueHealth’s true potential.

Conflict of Interest: Was the transaction the result of a flawed process driven by a conflicted board, heavily influenced by the controlling shareholder?

CURRENT SHAREHOLDERS OF NEUEHEALTH STOCK INTERESTED IN SEEKING ADDITIONAL INFORMATION ABOUT THE MERGER INVESTIGATION AND POTENTIAL LEGAL CLAIMS CAN CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected].